Staying true to our malaria mission in a time of global uncertainty

Message from the Chairman and CEO

It is 2021, and the world is still striving to emerge from the long, dark shadow of SARS-CoV-2, searching, as American poet Amanda Gorman1 says to find “find light in this never-ending shade”.

In 2020, Medicines for Malaria Venture (MMV) joined that search wholeheartedly. While keeping a strong focus on our core mission to discover, develop and deliver effective antimalarials for underserved populations, we expanded our work to include efforts to respond to COVID-19 in areas where we could make a unique contribution.

All hands on deck: contributing to the global pandemic response

Six years after the launch of the Global Health Security Agenda2 the world was nonetheless caught off guard by the rapid spread of SARS-CoV-2. At MMV, we contributed our core R&D and access strengths to the global effort (pp. 10-11). In response to supply chain issues, raised initially by our drug manufacturing partners, and given the intense interest in existing antimalarials as potential treatments for COVID-19, we joined forces with the World Health Organization (WHO), partners and major suppliers, advising on linkages with industry and coordinating efforts to monitor the supply chain and safeguard access to critical malaria commodities.

In addition, we swiftly sent antimalarial compound collections with potential SARS-CoV-2 activity to testing centres and distributed our open access compound collections to researchers free of charge. Since initiating the distribution of these compound collections, 125 copies of the Pandemic Response Box and 50 of the newly launched COVID Box, have been distributed, and shipments continue. We also supported clinical studies to repurpose existing medicines, including launching a Phase II clinical study in South Africa (p. 11).

Coming at malaria from all sides: prevention, treatment, radical cure

All the while, more than 400,000 people continue to lose their lives from malaria each year. As such, our core malaria work remains top priority, and together with our partners we continue to focus on expanding access to therapies that prevent, treat and cure both Plasmodium falciparum and Plasmodium vivax malaria.

Prevention

Young children urgently need protection from malaria, as they are the hardest hit by this disease. Despite challenges brought on by the COVID-19 pandemic, we helped ensure that the seasonal malaria chemoprevention (SMC) (pp. 25-28) programme for young children stayed on track in 13 implementing countries, helping protect 30 million children.

COVID-related disruptions did not unduly delay the distribution of this lifesaving intervention thanks to the exceptional effort of healthcare workers, government officials and political leadership. It is heartening that this success has also encouraged the expansion of SMC into new areas in the Sahel – in one example, three times as many children were reached in Nigeria in 2020 than in 2019.

Management of severe malaria

In Malawi, a study led by MMV on artesunate rectal capsules (ARC) generated important evidence demonstrating the role of toolkits and a formalized referral slip protocol in increasing the likelihood of a positive treatment outcome for patients. ARC is a pre-referral, lifesaving intervention for the very young with severe malaria. It halts the progression of the disease, giving time for patients to be transported to a health facility where they can be treated with injectable artesunate.

Another exciting development on the horizon is the novel injectable compound KAE609 (cipargamin), which is in Phase II trials in collaboration with Novartis as an alternative to standard treatment options for severe malaria.
treatment for severe malaria. This is particularly important in view of the recent identification of partial artemisinin resistance in Rwanda and several other African countries.

Radical cure

Our work to introduce and support the integration of tafenoquine (TQ) into P. vivax clinical management bore fruit – the first country in South East Asia to grant TQ marketing authorization approval, Thailand, also marked the first step to open up access to TQ across the Asia-Pacific, where P. vivax is becoming the more dominant malaria species. TQ was also submitted for approval in Myanmar, Vietnam, Philippines and Peru, while the paediatric dossier was submitted to the Australian Therapeutic Goods Administration (TGA).

Preparing for the next big global health crisis — Antimicrobial Resistance (AMR)

In 2020, reports of de novo artemisinin resistance in Rwanda were an urgent reminder of the need to step up surveillance for antimalarial drug resistance indicators both in the lab and the field. Although the artemisinin-based combination therapies (ACTs) AL and DHA-PQP continued to show cure rates of >95%, it is likely only a matter of time before ACTs, too, begin to lose their effectiveness as a treatment for uncomplicated P. falciparum malaria in the endemic regions of sub-Saharan Africa.

As with all forms of antimicrobial resistance, three things are required to prevent its rapid spread: to protect existing treatments, monitor their efficacy, and accelerate the development of next-generation medicines (pp. 12-17).

In the race against resistance, MMV’s strategy is to work with partners to develop simpler, effective, high-quality, patient-friendly medicines for adults and children that improve treatment adherence. Ganaplacide–lumefantrine is a leading combination currently in Phase IIb with Novartis for uncomplicated malaria. Behind that we have a healthy pipeline of compounds being assessed in various combinations, including for chemoprevention, through our Malaria Drug Development Catalyst. The Catalyst provides a legal and scientific platform to promote effective collaboration between industry partners, to facilitate decision-making on the most appropriate compounds for combination therapies and to accelerate the development of new drug combinations.

When it comes to finding ways to accelerate the discovery of new compounds, MMV continues to be a pioneer. We have established discovery networks and assay platforms to expedite identification of the most promising compounds against malaria as well as drug-resistant strains of other pathogens. In 2020, we developed two new tools to support the selection and dosage of compounds for combination therapies (pp. 38-39): the ACPR28 mathematical model and a mathematical application, MMVSola, named after the late Suresh Solapure, an MMV partner and an early champion of using pharmacokinetic/pharmacodynamic modelling to predict dosage, who tragically passed away in 2020.

Redressing the fatal gender imbalance

This year, MMV shone a stronger light on the unmet needs of pregnant women. Each year, malaria causes over 10,000 maternal and 200,000 newborn deaths. MMV and partners have committed to exploring innovative R&D strategies to identify new medicines that serve the needs of this population.

As a first step, we designed a far-sighted strategy, ‘MMBAs’ (p. 22) to generate more data on the impact of existing antimalarials on pregnant women, enrich the R&D pipeline with appropriate new drugs deemed low risk to mother and foetus, and advocate for earlier inclusion of pregnant and breastfeeding women in clinical trials than currently practiced. In 2020, this led to the launch of MMV and LSTM’s pregnancy registry (pp. 22-23) in three African countries to capture safety and exposure data on the real-life use of ACTs during all stages of pregnancy. Its aim is to support policy change through robust data, thereby improving treatment options for pregnant women suffering from malaria.

Prepared for an uncertain future...

2020 was an unprecedented year for global health. The MMV team, our Board, donors, indispensable partners and stakeholders demonstrated exemplary agility and adaptability at every level. We are grateful and inspired by their commitment and support.

As the SARS-CoV-2 virus continues to disrupt the economic, political, social and health systems of the world, the critical value of scientific research to global health security, and the preparedness, resilience and flexibility of the partnership model have been recognized. Both will continue to be needed.

Since 2009, the 13 malaria therapies that we have brought forward, together with our partners, have saved an estimated 2.7 million precious lives. While we remain resolute in our commitment to a malaria-free world, we also commit to sharing our expertise and experience when global health crises occur in the future. In this hyper-connected 21st century, we will work with partners to pursue the end of malaria and help ensure preparedness for the next impending global health crisis, for it will affect us all.

Dr David Reddy  Mr Per Wold-Olsen
CEO Chairman of the Board
(Left) (right)